Clinical Trials | October 30, 2023
SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers
Subscribe To Our Newsletter & Stay Updated
